News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
483,851 Results
Type
Article (22105)
Company Profile (164)
Press Release (461582)
Section
Business (143986)
Career Advice (1045)
Deals (27325)
Drug Delivery (50)
Drug Development (46462)
Employer Resources (98)
FDA (11810)
Job Trends (10683)
News (232229)
Policy (18280)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (6)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (6)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (1)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (1722)
Adcomms (3)
Allergies (56)
Alliances (41865)
ALS (41)
Alzheimer's disease (841)
Antibody-drug conjugate (ADC) (99)
Approvals (11845)
Artificial intelligence (247)
Autoimmune disease (10)
Automation (14)
Bankruptcy (217)
Best Places to Work (9097)
BIOSECURE Act (7)
Biosimilars (50)
Biotechnology (119)
Bladder cancer (38)
Brain cancer (17)
Breast cancer (168)
Cancer (1495)
Cardiovascular disease (83)
Career advice (910)
Career pathing (20)
CAR-T (114)
Cell therapy (329)
Cervical cancer (12)
Clinical research (37024)
Collaboration (677)
Compensation (171)
Complete response letters (8)
COVID-19 (1518)
CRISPR (36)
C-suite (165)
Cystic fibrosis (57)
Data (1302)
Decentralized trials (2)
Denatured (20)
Depression (19)
Diabetes (138)
Diagnostics (5815)
Digital health (18)
Diversity (6)
Diversity, equity & inclusion (24)
Drug discovery (87)
Drug pricing (36)
Drug shortages (16)
Duchenne muscular dystrophy (29)
Earnings (52892)
Editorial (11)
Employer branding (10)
Employer resources (90)
Events (69035)
Executive appointments (464)
FDA (12618)
Featured Employer (36)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (582)
Gene editing (85)
Generative AI (25)
Gene therapy (186)
GLP-1 (385)
Government (2166)
Grass and pollen (2)
Guidances (32)
Healthcare (13937)
Huntington's disease (10)
IgA nephropathy (11)
Immunology and inflammation (44)
Indications (18)
Infectious disease (1604)
Inflammatory bowel disease (79)
Inflation Reduction Act (4)
Influenza (36)
Intellectual property (68)
Interviews (172)
IPO (12966)
IRA (12)
Job creations (1980)
Job search strategy (753)
Kidney cancer (5)
Labor market (12)
Layoffs (202)
Leadership (11)
Legal (3821)
Liver cancer (53)
Lung cancer (218)
Lymphoma (91)
Machine learning (2)
Management (39)
Manufacturing (217)
MASH (24)
Medical device (13084)
Medtech (13089)
Mergers & acquisitions (14818)
Metabolic disorders (324)
Multiple sclerosis (29)
NASH (3)
Neurodegenerative disease (35)
Neuropsychiatric disorders (6)
Neuroscience (1085)
NextGen: Class of 2025 (5068)
Non-profit (2576)
Northern California (1496)
Now hiring (11)
Obesity (167)
Opinion (131)
Ovarian cancer (59)
Pain (55)
Pancreatic cancer (61)
Parkinson's disease (83)
Partnered (15)
Patents (158)
Patient recruitment (68)
Peanut (37)
People (40586)
Pharmaceutical (31)
Pharmacy benefit managers (5)
Phase I (13518)
Phase II (16251)
Phase III (11285)
Pipeline (697)
Podcasts (41)
Policy (38)
Postmarket research (957)
Preclinical (5481)
Press Release (67)
Prostate cancer (58)
Psychedelics (13)
Radiopharmaceuticals (224)
Rare diseases (196)
Real estate (4269)
Recruiting (39)
Regulatory (13450)
Reports (21)
Research institute (1704)
Resumes & cover letters (164)
Rett syndrome (3)
RNA editing (2)
RSV (21)
Schizophrenia (24)
Series A (102)
Series B (65)
Service/supplier (11)
Sickle cell disease (22)
Southern California (1474)
Special edition (1)
Spinal muscular atrophy (81)
Sponsored (22)
Startups (2912)
State (2)
Stomach cancer (3)
Supply chain (41)
The Weekly (20)
United States (14917)
Vaccines (398)
Venture capitalists (23)
Webinars (9)
Weight loss (97)
Women's health (21)
Worklife (7)
Date
Today (19)
Last 7 days (416)
Last 30 days (1909)
Last 365 days (24619)
2025 (5569)
2024 (26114)
2023 (30336)
2022 (40319)
2021 (43279)
2020 (41518)
2019 (35634)
2018 (26709)
2017 (24681)
2016 (22859)
2015 (26775)
2014 (19824)
2013 (16705)
2012 (18271)
2011 (18465)
2010 (16394)
Location
Africa (475)
Alabama (41)
Alaska (6)
Arizona (136)
Arkansas (11)
Asia (30208)
Australia (5057)
California (3703)
Canada (1389)
China (347)
Colorado (192)
Connecticut (179)
Delaware (107)
Europe (65912)
Florida (637)
Georgia (158)
Idaho (48)
Illinois (366)
India (17)
Indiana (246)
Iowa (6)
Japan (125)
Kansas (91)
Kentucky (16)
Louisiana (7)
Maine (54)
Maryland (558)
Massachusetts (2711)
Michigan (205)
Minnesota (312)
Mississippi (2)
Missouri (69)
Montana (27)
Nebraska (20)
Nevada (36)
New Hampshire (68)
New Jersey (1180)
New Mexico (23)
New York (1093)
North Carolina (709)
North Dakota (8)
Northern California (1496)
Ohio (135)
Oklahoma (13)
Oregon (22)
Pennsylvania (828)
Puerto Rico (8)
Rhode Island (24)
South America (732)
South Carolina (17)
South Dakota (1)
Southern California (1474)
Tennessee (71)
Texas (580)
Utah (114)
Virginia (81)
Washington D.C. (25)
Washington State (375)
West Virginia (3)
Wisconsin (51)
483,851 Results for "sol gel technologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
PreveCeutical to Develop Sol-Gel N2B Platform for Parkinson’s Disease
February 6, 2025
·
6 min read
Press Releases
Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects
February 4, 2025
·
6 min read
Business
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Technologies, Ltd. today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 20, 2024
·
13 min read
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
Sol-Gel Technologies, Ltd. announced that it received a notification letter on May 21 2024, from the Nasdaq Stock Market LLC Listing Qualifications Department, stating that the Company is not in compliance with the requirement to maintain a minimum bid price of $1 per share, as set forth in Rule 5450 of the Nasdaq Listing Rules, since the closing bid price for the Company’s ordinary Shares listed on Nasdaq was below US$1.00 for 33 consecutive business days.
May 28, 2024
·
6 min read
Drug Development
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”) today announced that it has begun Phase 3 testing of SGT-610 (patidegib gel, 2%) for Gorlin syndrome with the first patient screened.
November 30, 2023
·
7 min read
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Sol-Gel Technologies, Ltd. announced that Padagis Israel Pharmaceuticals Ltd, Sol-Gel’s collaboration partner, submitted a first-to-file Abbreviated New Drug Application to the U.S. Food and Drug Administration for Roflumilast Cream, 0.3%, a drug product generic to Zoryve® Cream, indicated for the treatment of plaque psoriasis in patients six years of age and older.
April 1, 2024
·
6 min read
Deals
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Sol-Gel Technologies, Ltd. announced that it has signed an asset purchase agreement with Chinese based Shenzhen Beimei Pharmaceutical Co. Ltd, for the commercialization of TWYNEO, for the treatment of acne vulgaris, in the mainland of China, Hong Kong, Macau, Taiwan and Israel.
May 16, 2024
·
7 min read
Press Releases
Sol-Gel Technologies Announces Management Realignment
July 15, 2024
·
6 min read
Press Releases
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 15, 2024
·
15 min read
Press Releases
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
November 20, 2024
·
6 min read
1 of 48,386
Next